152 related articles for article (PubMed ID: 10209962)
1. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
[TBL] [Abstract][Full Text] [Related]
2. T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.
Kumamaru W; Nakamura S; Kadena T; Yamada A; Kawamura E; Sasaki M; Ohyama Y; Toyoshima T; Hayashida JN; Itoh K; Shirasuna K
Int J Cancer; 2004 Feb; 108(5):686-95. PubMed ID: 14696095
[TBL] [Abstract][Full Text] [Related]
3. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
[TBL] [Abstract][Full Text] [Related]
4. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
[TBL] [Abstract][Full Text] [Related]
5. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
[TBL] [Abstract][Full Text] [Related]
6. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes.
Oiso M; Eura M; Katsura F; Takiguchi M; Sobao Y; Masuyama K; Nakashima M; Itoh K; Ishikawa T
Int J Cancer; 1999 May; 81(3):387-94. PubMed ID: 10209953
[TBL] [Abstract][Full Text] [Related]
7. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.
Arai J; Yasukawa M; Ohminami H; Kakimoto M; Hasegawa A; Fujita S
Blood; 2001 May; 97(9):2903-7. PubMed ID: 11313288
[TBL] [Abstract][Full Text] [Related]
8. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
[TBL] [Abstract][Full Text] [Related]
9. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204
[TBL] [Abstract][Full Text] [Related]
10. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T
Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
[TBL] [Abstract][Full Text] [Related]
12. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
[TBL] [Abstract][Full Text] [Related]
13. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL.
Nakao M; Shichijo S; Imaizumi T; Inoue Y; Matsunaga K; Yamada A; Kikuchi M; Tsuda N; Ohta K; Takamori S; Yamana H; Fujita H; Itoh K
J Immunol; 2000 Mar; 164(5):2565-74. PubMed ID: 10679095
[TBL] [Abstract][Full Text] [Related]
14. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24.
Katsura F; Eura M; Chikamatsu K; Oiso M; Yumoto E; Ishikawa T
Jpn J Clin Oncol; 2000 Mar; 30(3):117-21. PubMed ID: 10798537
[TBL] [Abstract][Full Text] [Related]
15. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
Kobayashi K; Noguchi M; Itoh K; Harada M
Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
[TBL] [Abstract][Full Text] [Related]
16. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
[TBL] [Abstract][Full Text] [Related]
18. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
19. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
